GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AS AN ADJUNCT TO AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR LYMPHOMA

被引:121
作者
ADVANI, R
CHAO, NJ
HORNING, SJ
BLUME, KG
AHN, DK
LAMBORN, KR
FLEMING, NC
BONNEM, EM
GREENBERG, PL
机构
[1] STANFORD UNIV, MED CTR, DIV HEMATOL 161, STANFORD, CA 94305 USA
[2] NO CALIF CANC CTR, BELMONT, CA USA
[3] SCHERING PLOUGH CORP, KENILWORTH, NJ USA
关键词
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; TRANSPLANTATION; AUTOLOGOUS; HODGKINS DISEASE; LYMPHOMA; NON-HODGKIN;
D O I
10.7326/0003-4819-116-3-183
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the hemopoietic effects of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients having autologous hemopoietic stem cell transplantation for Hodgkin or non-Hodgkin lymphoma. Design: Placebo or GM-CSF was administered after bone marrow or peripheral blood stem cell transplantation or both in a randomized, double-blind phase III trial by daily intravenous infusion (10-mu-g/kg body weight) until absolute neutrophil counts reached greater-than-or-equal-to 1000/mm3 on 3 consecutive days. Setting: Bone marrow transplantation unit in a university hospital. Patients: Sixty-nine consecutive patients with Hodgkin or non-Hodgkin lymphoma received GM-CSF (36 patients) or placebo (33 patients). Measurements and Main Results: Patients who received GM-CSF achieved absolute neutrophil counts greater-than-or-equal-to 500/mm3 (median, 12 compared with 16 days, P = 0.02) and absolute neutrophil counts greater-than-or-equal-to 1000/mm3 (median, 15 compared with 24 days, P < 0.001) more quickly than patients who received placebo. Multivariate analysis indicated that use of GM-CSF, peripheral blood stem cells, and unpurged bone marrow were the strongest predictors for early neutrophil recovery > 500/mm3. Bacterial infections were significantly reduced in the GM-CSF group (P = 0.04). Delayed engraftment (neutrophils < 500/mm3 at day 30) occurred in 26% and 17% of the placebo and GM-CSF groups, respectively, and correlated with the absence of detectable myeloid progenitor cells (colony-forming units-granulocyte macrophage, CFU-GM) (P < 0.001) in marrow aspirate specimens obtained on day 15. Time to platelet independence, duration of hospital stay, severe adverse reactions, relapse, and disease-free survival rates did not differ significantly between the two groups. Conclusions: Administration of GM-CSF after autologous hemopoietic stem cell transplantation in patients with lymphoma resulted in accelerated myeloid recovery, particularly in patients who received peripheral blood stem cells and nonpurged bone marrow, and was associated with a decreased incidence of bacterial infections.
引用
收藏
页码:183 / 189
页数:7
相关论文
共 28 条
[1]  
ADVANI R, 1990, BLOOD S, V76, pA525
[2]  
APPELBAUM FR, 1978, BLOOD, V52, P85
[3]  
BENNETT CL, 1990, BLOOD S, V76, pA132
[4]  
BLAZAR BR, 1989, BLOOD, V73, P849
[5]   EFFECT OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR ON HEMATOPOIETIC RECONSTITUTION AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
BRANDT, SJ ;
PETERS, WP ;
ATWATER, SK ;
KURTZBERG, J ;
BOROWITZ, MJ ;
JONES, RB ;
SHPALL, EJ ;
BAST, RC ;
GILBERT, CJ ;
OETTE, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (14) :869-876
[6]  
DEVITA VT, 1985, PRINCIPLES PRACTICE, P67
[7]   HEMATOPOIETIC RESPONSES IN PATIENTS WITH ADVANCED MALIGNANCY TREATED WITH RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [J].
HERRMANN, F ;
SCHULZ, G ;
LINDEMANN, A ;
MEYENBURG, W ;
OSTER, W ;
KRUMWIEH, D ;
MERTELSMANN, R .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (02) :159-167
[8]   THE STANFORD EXPERIENCE WITH HIGH-DOSE ETOPOSIDE CYTOREDUCTIVE REGIMENS AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA - PRELIMINARY DATA [J].
HORNING, SJ ;
CHAO, NJ ;
NEGRIN, RS ;
HOPPE, RT ;
KWAK, LW ;
LONG, GD ;
STALLBAUM, B ;
OCONNOR, P ;
BLUME, KG .
ANNALS OF ONCOLOGY, 1991, 2 :47-50
[9]  
KESSINGER A, 1988, BLOOD, V71, P723
[10]  
KIRK JL, 1988, CANCER-AM CANCER SOC, V62, P2445, DOI 10.1002/1097-0142(19881201)62:11<2445::AID-CNCR2820621133>3.0.CO